Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Respiratory Papillomatosis: early-phase trial registry
4 of 7 indexed Recurrent Respiratory Papillomatosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Recurrent Respiratory Papillomatosis: 7 US clinical trials tracked, 4 recruiting.
Recurrent Respiratory Papillomatosis is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Precigen, running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-respiratory-papillomatosis
OPEN 4 | RECR 57% | LATE 1 | EARLY 5 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)
Recurrent Respiratory Papillomatosis lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Respiratory Papillomatosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Respiratory Papillomatosis is recruiting above its size-band peers.
4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Respiratory Papillomatosis research.
Precigen accounts for 2 of 7 trials (28.6%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Respiratory Papillomatosis trials plan to enrol fewer than 100 people.
Median target enrolment is 21 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.
-
Recurrent Respiratory Papillomatosis research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
Massachusetts General Hospital
NCT06412172
Zopa Retreatment and Vector Shedding in Adults With RRP
Precigen
NCT06538480
Merck IIT: RRP Pembro and Lenvatinib
Yale University
NCT04645602
Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients
Mayo Clinic
NCT07317154
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
Precigen
NCT04724980
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
Massachusetts General Hospital
NCT02632344
Avelumab for People With Recurrent Respiratory Papillomatosis
National Cancer Institute (NCI)
NCT02859454
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Respiratory Papillomatosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Respiratory Papillomatosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Respiratory Papillomatosis page
7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Recurrent Respiratory Papillomatosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Precigen sponsors the most Recurrent Respiratory Papillomatosis trials on record, review their full trial history before evaluating a specific study. See Precigen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Respiratory Papillomatosis condition card totals 7 registered trials; most-linked intervention Pembrolizumab; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.